Next Phase Newsletter

A venture capital firm headquartered in Asia invests in breakthrough technologies changing healthcare. The firm invests from seed-Series A. The fund’s LP’s include groups in the healthcare sector.

The firm invests in early stage life science startups with a focus on breakthrough technologies and sciences in healthcare. This includes genomic and synthetic biology technologies, digital health, ML/AI, therapeutics and diagnostics. The firm focuses on pre-IND assets in therapeutics. For technologies regulated as medical devices, the firm focuses on smart medical devices in the pre-commercial stage.

The firm’s partners have a strong clinical perspective; the firm has the capability to help portfolio companies develop clinical resources, and has helped academic scientists form companies to commercialize their discoveries.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm with offices in USA and Asia manages over $750 million in committed capital across 8 funds. The most recent fund closed in 2016. The firm focuses on early stage companies in Technology and Healthcare sectors with an initial investment size ranging from $500k to $5M.The firm primarily looks to invest in companies based in China and US.

The firm is currently looking for new investment opportunities in Diagnostics, Medical Devices, Healthcare IT and Advanced Materials sectors. The firm is very opportunistic in terms of subsectors and indications, and is open to all classes of devices. The firm prefers to invest companies in pre-clinical and clinical stage, but it is open to consider companies with products on the market. Historically, the firm was active in companies developing diagnostic services and instrumentation, fetal monitoring and ultrasound systems, a stem cell bank, numerous health IT and vascular closure devices.

The firm invests in both private and public companies with a strong management team. The firm doesn’t have specific requirements for companies’ revenue or EBITDA. The firm looks to take a Board seat post investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A joint venture investment company launched by two large corporations strives to catalyze the success of digital medicine products, services and business models by investing in early-stage companies and leveraging its extensive networks in Pharma, Mobile/IT, and investment community. The firm prefers to co-invest and makes equity investments of up to $5 million per deal. The firm is currently seeking opportunities in the US, EU, and Israel.

The firm is seeking entrepreneurs using digital technology to transform pharmaceutical products, sales and marketing, R&D, and enterprise operations. The firm also considers personalized medicine using -omics science. Examples may include enterprise software solutions that improves clinical care or mobile sensors for disease management in home care settings. The firm is less interested in consumer products. The firm is seeking products with some market traction or credible customers.

The firm works with strong founders who demonstrate full understanding of their market sector.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A USA-based investment firm is currently investing in early stage biotechnology companies and company creation/spinout/licensing opportunities from dedicated capital. These investments are typically standalone and/or syndicated with a network of investors that have invested with the firm in the past. The firm founds 1-2 companies per year by creating a company around an asset that they acquired or in-licensed. The firm also considers investments in 0-2 existing companies per year, which are typically early in the company’s development and/or follow-on investments. The firm invests globally but requires the company or development programs have a North America component.

The firm is a flexible and opportunistic investor and will consider any therapeutics area, primarily in specialty areas of medicine with a focus on niche areas of medicine and smaller indications, including rare orphan diseases. The firm focuses on drug development and makes occasional investments in therapeutic devices. The firm focuses on clinical stage drug development opportunities, but may consider earlier stage products if the drug is a repositioning/reformulation opportunity or has some human safety data in another indication and/or territory. The firm will generally focus on single therapeutic assets and avoids diagnostics, platforms, and computational biology companies that lack any drug assets.

The firm is open to both lead and co-investing depending on the opportunity. However, typically the firm will not be a lead on a large raise. If the firm creates the company they will be a very active, hands-on investor. The firm is open to investing in very young companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in the USA is focused on women’s health and is looking to invest in early-stage companies that develop related technologies. The firm seeks to engage in seed to series A financing rounds and the typical allocation size is up to 1 million USD. The firm is open to both leading and co-investing and is likely to seek a board seat. The firm will consider opportunities across the U.S and is looking to make up to 5 new investments in the next 12 months.

The firm will consider therapeutics, diagnostics, medical devices and digital health as long as the technologies are related to women’s health. The firm is focused on conditions that “affect only women, affect mostly women, and are worse in women”. Within the above categories, the firm will consider all subsectors and indications, including obstetrics and gynecology, cardiology, neurology, infectious diseases, and orphan drugs. The firm is flexible about the phase of development and will consider companies that are relatively early. In general, the firm will consider therapeutics companies that are pre-clinical stages with strong early data and device and diagnostics companies that are in early models of development.

The firm does not have specific requirement for company’s management team. The firm is likely to take a board seat in its portfolio companies and act as an active investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A global leader in life sciences, diagnostics and applied chemical markets providing services, equipment, and support solutions to laboratories worldwide has an Early Stage Partnership Program that works with, and potentially invests in, early proof-of-concept to revenue stage companies that are a strategic fit the firm’s core products and services. Apart from financial investing, the firm provides strategic support to the companies with whom they partner. While the firm will partner globally, it has primarily partnered with US and European companies to this point.

The firm partners with early stage companies that provide game-changing tools, technologies and applications to advance the Life Science Research, Clinical Research and Diagnostic markets. Within these markets, the firm is especially interested in the fields of Cellular Reprogramming, Cellular Manufacturing/Bioprocessing, Data Analytics, Informatics, Molecular Diagnostics, Omics, Single Cell Analysis and Systems Biology. The firm is currently not considering therapeutics or medical devices. The firm has partnered with companies early in proof of concept and up to revenue-generating companies.

The firm’s Early Stage Partnership program will only invest in companies that are a strategic fit, but operates as a financial investor, separating any strategic partnerships from the financial investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A firm based in Western Europe focuses on investment opportunities in Europe but is open to considering investments in China as well. Initial equity-investments range in size from € 1 million up to € 10 million.

The firm invests broadly within the healthcare sector, and manages funds in Health-tech, Sustainable Chemistry, Digital Growth (with a focus on digital health and Industry 4.0).

The firm’s funds invest in companies that are in revenue stage or pre-revenue stage provided that the technologies and products are disruptive and have the potential to significantly address global markets.

The firm looks for exceptional management teams but is ready to support its portfolio companies in building their organization and being a sparring partner for strategy and business development discussions.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.